Wu Ke, Zhao Long, Wang Tiangang, Yang Jiayue, Zhao Yueshui, Du Fukuan, Chen Yu, Deng Shuai, Shen Jing, Xiao Zhangang, Liu Jingwen, Yang Ruhan, Li Xi, Li Hua, Li Wanping, Li Xiaobing, Sun Yuhong, Gu Li, Wu Xu, Li Mingxing
Cell Therapy & Cell Drugs Key Laboratory of Luzhou, Department of Pharmacology, School of Pharmacy, Southwest Medical University, 646000, Luzhou, Sichuan, China; South Sichuan Institute of Translation Medicine, 646000, Luzhou, Sichuan, China.
Department of Spleen and Stomach Diseases, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, 646000, Luzhou, Sichuan, China.
J Ethnopharmacol. 2025 Aug 23;353(Pt B):120465. doi: 10.1016/j.jep.2025.120465.
Alcoholic liver disease (ALD), a chronic liver injury induced by prolonged alcohol consumption, involves intricate multi-organ interactions, such as gut-liver axis disruption, as well as the synergistic effects of multiple factors including oxidative stress, intestinal dysbiosis, and metabolic disturbances. These complex pathological mechanisms render single-target therapies largely ineffective in achieving desirable therapeutic outcomes. Traditional Chinese medicine (TCM), characterized by its multi-target mechanisms and low toxicity, has demonstrated unique advantages in the treatment of ALD in the past decades.
This article aims to review recent research progress on TCM for ALD treatment, focusing on experimental studies and clinical validation of both single and combined TCM formulations as well as their active components. It seeks to comprehensively analyze the pharmacological mechanisms and therapeutic efficacy of TCM in ALD intervention, highlighting key targets and clinical translational potential.
To systematically review research progress on TCM for ALD, a comprehensive literature search (covering from 1996 to 2025) was conducted across PubMed, Web of Science, and CNKI databases. Search strategies employed combined subject headings and free-text terms, using core Boolean logic: (ALD-related terms) AND (TCM/herbal medicine-related terms) NOT (Non-alcoholic liver disease). Documents without DOIs and those with suboptimal study designs (e.g., lacking proper controls, inadequate methodological description, absence of herbal quality control, or insufficient mechanistic exploration) were excluded. Eligible studies focusing on TCM compound formulas, single herbs, and active ingredients as primary interventions for ALD were analyzed to provide an integrated foundation for this review. Plant names were verified through the Multilingual Plant Name Server (MPNS, http://mpns.kew.org).
Recent studies demonstrate that TCM interventions effectively address the multifactorial nature of ALD by targeting oxidative stress, restoring gut-liver axis balance, modulating intestinal flora, and correcting metabolic abnormalities. Both single and combined TCM formulations as well as some of their active components have shown promising results in experimental and/or clinical settings, underscoring their multi-target advantages. Despite their potential, significant limitations remain in the current research, necessitating more comprehensive studies on the potent bioactive components, potential pharmacological effects, specific targets, and clinical value.
TCM offers a promising therapeutic strategy for ALD due to its ability to simultaneously target multiple pathological mechanisms. This review highlights the potential of TCM in ALD treatment and provides a foundation for future research and clinical applications, emphasizing the need for further exploration of its pharmacological mechanisms and therapeutic efficacy.
酒精性肝病(ALD)是一种因长期饮酒导致的慢性肝损伤,涉及复杂的多器官相互作用,如肠-肝轴破坏,以及氧化应激、肠道菌群失调和代谢紊乱等多种因素的协同作用。这些复杂的病理机制使得单一靶点治疗在实现理想治疗效果方面大多无效。中药以其多靶点作用机制和低毒性为特点,在过去几十年的ALD治疗中显示出独特优势。
本文旨在综述中药治疗ALD的最新研究进展,重点关注单味中药配方、复方中药配方及其活性成分的实验研究和临床验证。旨在全面分析中药在ALD干预中的药理机制和治疗效果,突出关键靶点和临床转化潜力。
为系统综述中药治疗ALD的研究进展,在PubMed、Web of Science和CNKI数据库中进行了全面的文献检索(涵盖1996年至2025年)。检索策略采用主题词和自由文本词相结合的方式,运用核心布尔逻辑:(与ALD相关的术语)AND(与中药/草药相关的术语)NOT(非酒精性肝病)。排除没有数字对象标识符(DOI)的文献以及研究设计欠佳的文献(例如,缺乏适当对照、方法描述不充分、缺乏草药质量控制或机制探索不足)。对以中药复方、单味中药和活性成分作为ALD主要干预措施的合格研究进行分析,为本次综述提供综合依据。植物名称通过多语言植物名称服务器(MPNS,http://mpns.kew.org)进行核实。
近期研究表明,中药干预通过针对氧化应激、恢复肠-肝轴平衡、调节肠道菌群和纠正代谢异常,有效应对了ALD的多因素性质。单味中药配方、复方中药配方及其一些活性成分在实验和/或临床环境中均显示出有前景的结果,凸显了它们的多靶点优势。尽管具有潜力,但当前研究仍存在重大局限性,需要对有效的生物活性成分、潜在药理作用、特定靶点和临床价值进行更全面的研究。
由于中药能够同时针对多种病理机制,因此为ALD提供了一种有前景的治疗策略。本综述突出了中药在ALD治疗中的潜力,并为未来研究和临床应用奠定了基础,强调需要进一步探索其药理机制和治疗效果。